Zoetis EVP Roxanne Lagano Cashes Out $500K in Shares
December 16, 2023
☀️Trending News
Zoetis Inc ($NYSE:ZTS). is a publicly traded animal health company that engages in the discovery, development, manufacturing, and commercialization of veterinary vaccines and medicines. The company is the largest animal health company in the world and is headquartered in New Jersey. Recently, Roxanne Lagano, the executive vice president of Zoetis, has disposed of $500K worth of shares. These two transactions have resulted in a total of over $1 million worth of shares being sold by the executive.
Despite this news, investors remain confident in Zoetis and the overall financial health of the company. Investors also remain hopeful that its strong portfolio of animal medicines and vaccines will continue to drive strong financial performance in the future.
Price History
On Thursday, ZOETIS INC (NYSE: ZTS) witnessed a positive day with its stock opening at $198.0 and closing at $200.1, up by 1.4% from last closing price of 197.4. This boost in share prices came after the company’s Executive Vice President and Chief Financial Officer Roxanne Lagano cashed out $500K in shares. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for Zoetis Inc. More…
| Total Revenues | Net Income | Net Margin |
| 8.37k | 2.28k | 28.4% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Zoetis Inc. More…
| Operations | Investing | Financing |
| 2k | -883 | -904 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Zoetis Inc. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 13.75k | 9.13k | 10.05 |
Key Ratios Snapshot
Some of the financial key ratios for Zoetis Inc are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 8.6% | 10.6% | 37.3% |
| FCF Margin | ROE | ROA |
| 15.4% | 42.2% | 14.2% |
Analysis
GoodWhale has performed an analysis of ZOETIS INC‘s wellbeing, and based on our Star Chart, we have classified them as a ‘rhino’, which indicates that the company has achieved moderate revenue or earnings growth. This type of company may be of interest to investors who are looking for steady growth or a reliable dividend. ZOETIS INC has a high health score of 9/10, which indicates that the company is well equipped with cashflows and debt that can sustain future operations even in times of crisis. Additionally, GoodWhale has rated ZOETIS INC positively in terms of dividend, growth, and profitability. The company has also been given a medium rating in terms of asset. More…
Peers
Zoetis Inc. is a global animal health company that develops, manufactures, and markets a wide range of veterinary products. The company’s products include vaccines, parasiticides, pharmaceuticals, diagnostics, and biologics. Zoetis Inc. has a broad portfolio of products that are used in the prevention, treatment, and control of disease in animals. The company’s competitors include BioGaia AB, Krka d.d., and Phibro Animal Health Corp.
– BioGaia AB ($OTCPK:BIOGY)
Biogaia is a Swedish biotech company that markets probiotic products for infants, children, and adults. The company’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
Biogaia’s market cap is 800.05M as of 2022. The company has a Return on Equity of 10.86%. Biogaia’s products are based on the lactic acid bacterium Lactobacillus reuteri, which is found naturally in the human gastrointestinal tract. Biogaia’s products are sold in over 60 countries worldwide.
– Krka d.d. ($LTS:0HLK)
Krka d.d. is a Slovenian pharmaceutical company. It is the largest pharmaceutical company in Slovenia and one of the largest in the Balkans. The company was founded in 1959 and is headquartered in Novo mesto. Krka d.d. has a market cap of 2.77B as of 2022 and a Return on Equity of 12.85%. The company’s main products are prescription drugs, over-the-counter drugs, and medical devices.
– Phibro Animal Health Corp ($NASDAQ:PAHC)
Phibro Animal Health Corporation is a diversified animal health and specialty ingredients company with products in over 100 countries. The company’s products are sold through veterinarians, distributors, and feed stores. Phibro Animal Health Corporation’s mission is to improve the health and productivity of animals. The company’s products are used in a variety of animals, including cattle, swine, poultry, and aquaculture. Phibro Animal Health Corporation’s products are designed to improve the health and productivity of animals while providing a safe and healthy environment for them to live in.
Summary
Investors in Zoetis Inc. have recently been alerted to an executive sale of shares worth $500K. This comes after the stock had surged following strong earnings and sales guidance from the company. Analysts believe this could be a signal of insider knowledge that the company is overvalued at current prices and could be a sign to begin selling some of the position.
Short term traders should take caution, as such news could signal a potential downturn in the stock in the coming weeks or months. Those with a longer-term view may benefit from research into the company’s financials to ensure it is a sound investment.
Related Posts
Recent Posts
